Cerity Partners
BNTX icon

Cerity Partners’s BioNTech BNTX Stock Holding History

Cerity Partners’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,407
Closed -$363K – 2759
2025
Q2 		$363K Sell
3,407
-510
-13% -$51.5K ﹤0.01% 2044
2025
Q1 		$357K Buy
+3,917
New +$439K ﹤0.01% 1935
2024
Q3 		– Sell
-3,967
Closed -$319K – 2542
2024
Q2 		$319K Sell
3,967
-856
-18% -$78.2K ﹤0.01% 1784
2024
Q1 		$445K Buy
+4,823
New +$462K ﹤0.01% 1655
2023
Q2 		– Sell
-20,648
Closed -$2.57M – 1682
2023
Q1 		$2.57M Buy
20,648
+72
+0.3% +$9.89K 0.01% 640
2022
Q4 		$3.09M Buy
+20,576
New +$3.17M 0.02% 451

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Cerity Partners's BNTX Position: Q3 2025 in Review

Cerity Partners sold out of BioNTech (BNTX) in Q3 2025, closing a stake of 3,407 shares — an estimated $363K sold.

Cerity Partners first reported a position in BNTX in Q4 2022 and held it in 6 quarters. The position peaked at $3.09M in Q4 2022. 254 funds tracked by Wall St. Rank hold BNTX as of Q3 2025.

  • Cerity Partners reported no remaining BioNTech position as of Q3 2025 after selling out during the quarter.
  • Cerity Partners sold 3,407 BioNTech shares in Q3 2025, an estimated $363K.
  • Cerity Partners first reported a position in BioNTech in Q4 2022 and held it in 6 quarters.
  • Cerity Partners's BioNTech position peaked at $3.09M in Q4 2022.
  • 254 funds tracked by Wall St. Rank held BioNTech as of Q3 2025.

Based on Cerity Partners's 13F filing for Q3 2025, filed 22 Oct 2025.